Table 3.

Predictors of BMI z score in children and adolescents during antipsychotic treatment—final model

Model 3	< 15 weeks follow-upa				15–52 weeks follow-upa				> 52 weeks follow-upa
	β	p value	SE	95% CI	β	p value	SE	95% CI	β	p value	SE	95% CI
Dose equivalent/kg	− 0.02	0.812	0.08	− 0.17 to 0.13	0.01	0.941	0.17	− 0.31 to 0.34	− 0.05	0.295	0.05	− 0.14 to 0.04
× Duration of use (weeks)	0.01	0.127	0.01	0.00 to 0.03	0.00	0.839	0.01	− 0.01 to 0.01	0.00	0.826	0.00	0.00 to 0.00
Baseline BMI z score	0.99	< 0.001	0.02	0.95 to 1.03	0.83	< 0.001	0.11	0.61 to 1.04	0.65	< 0.001	0.08	0.50 to 0.80
× Duration of use (weeks)	− 0.01	< 0.001	0.00	− 0.02 to 0.01	0.00	0.565	0.00	− 0.01 to 0.00	0.00	0.322	0.00	0.00 to 0.00
Previous antipsych. Drug (no)	0.00	0.975	0.06	− 0.11 to 0.11	0.09	0.782	0.31	− 0.52 to 0.69	0.22	0.284	0.20	− 0.18 to 0.62
× Duration of use (weeks)	0.02	0.003	0.01	0.01 to 0.03	0.00	0.994	0.01	− 0.02 to 0.02	0.00	0.301	0.00	0.00 to 0.00
No stimulant	0.10	0.074	0.06	− 0.01 to 0.21	0.38	0.009	0.15	0.09 to 0.67	0.35	< 0.001	0.10	0.16 to 0.55
× Duration of use (weeks)	0.02	0.002	0.01	0.01 to 0.03	0.01	0.378	0.01	− 0.01 to 0.02	0.00	0.010	0.00	0.00 to 0.00

^a < 15 weeks: n = 144 patients, 15–52 weeks 111 patients, > 52 weeks: 58 patients